Skip to main content

Table 7 Outcomes predicted by models for one birth cohort in Afr-region

From: Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world

  POLYMODa Roxanne CoRoVa
Undiscounted cases    
   Mild 92,989 121,312 128,807
   Moderate 49,051 70,126 54,559
   Severe 5,092 9,589 5,277
   Nosocomial 1,680 1,986 2,701
   Deaths 955 1,789 1,524
   Outpatient 54,143 70,126 54,559
   Inpatient (comm. acq.) 5,092 9,589 5,277
Discounted savings    
   Outpatient $568,502 $716,305 $623,977
   Inpatient $973,247 $1,329,538 $753,884
   Indirect $108,916 $106,377 $81,486
   Discounted net costsb (*1000) $6,759 $ 8,757-17,094 $ 9,250-17,467
Discounted QALYs    
   Mortality 24,962 45,817 39,070
   Morbidity 542 762 628
  1. a. Approximation for one cohort from the multi-cohort results; b. Health-care perspective and range given for previous upper and lower vaccine prices if appropriate.